Have you looked into how Phibro Animal Health (PAHC Quick QuotePAHC - Free Report) performed internationally during the quarter ending September 2026? Considering the widespread global presence of this maker of animal health products and nutritional supplements, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.

In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importance on grasping the extent of a company's dependence on international markets, as it sheds light on the firm's earnings stability, its skill in leveraging various economic cycles and its broad growth potential.

Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

While delving into PAHC's performance for the past quarter, we observed some fascinating trends in the revenue from its foreign segments that are commonly modeled and observed by analysts on Wall Street.

The company's total revenue for the quarter amounted to $386.8 million, showing rise of 6.3%. We will now explore the breakdown of PAHC's overseas revenue to assess the impact of its international operations.

A Closer Look at PAHC's Revenue Streams Abroad

Of the total revenue, $49.71 million came from Europe, Middle East and Africa during the last fiscal quarter, accounting for 12.9%. This represented a surprise of +8.38% as analysts had expected the region to contribute $45.87 million to the total revenue. In comparison, the region contributed $53.75 million, or 13.6%, and $44.94 million, or 12.4%, to total revenue in the previous and year-ago quarters, respectively.

During the quarter, Latin America and Canada contributed $88.49 million in revenue, making up 22.9% of the total revenue. When compared to the consensus estimate of $94.6 million, this meant a surprise of -6.46%. Looking back, Latin America and Canada contributed $90.22 million, or 22.7%, in the previous quarter, and $87.23 million, or 24%, in the same quarter of the previous year.

Asia Pacific generated $32.5 million in revenues for the company in the last quarter, constituting 8.4% of the total. This represented a surprise of +15.57% compared to the $28.12 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia Pacific accounted for $32.52 million (8.2%), and in the year-ago quarter, it contributed $29.38 million (8.1%) to the total revenue.

Revenue Forecasts for the International Markets

It is projected by analysts on Wall Street that Phibro will post revenues of $389.59 million for the ongoing fiscal quarter, an increase of 4.2% from the year-ago quarter. The expected contributions from Europe, Middle East and Africa, Latin America and Canada and Asia Pacific to this revenue are 11.7%, 24.3%, and 5.6%, translating into $45.39 million, $94.75 million, and $21.82 million, respectively.

For the full year, the company is projected to achieve a total revenue of $1.58 billion, which signifies a rise of 3.9% from the last year. The share of this revenue from various regions is expected to be: Europe, Middle East and Africa at 12.3% ($193.44 million), Latin America and Canada at 23.3% ($368 million), and Asia Pacific at 7.3% ($114.66 million).

In Conclusion

Phibro's reliance on international markets for revenues offers both opportunities and risks. Hence, keeping an eye on its international revenue trends could significantly help forecast the company's prospects.

In an environment where global interconnections and geopolitical skirmishes are intensifying, Wall Street analysts keep a keen eye on these trends, particularly for firms with overseas operations, to adjust their earnings predictions. Moreover, a range of other aspects, including how a company fares in its home country, significantly affects these projections.

Here at Zacks, we put a great deal of emphasis on a company's changing earnings outlook, as empirical research has shown that's a powerful force driving a stock's near-term price performance. Quite naturally, the correlation is positive here -- an upward revision in earnings estimates drives the stock price higher.

The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.

Phibro, bearing a Zacks Rank #2 (Buy), is expected to outperform the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Phibro Animal Health's Recent Stock Market Performance

The stock has witnessed a decline of 13.9% over the past month versus the Zacks S&P 500 composite's a decrease of 5.6%. In the same interval, the Zacks Medical sector, to which Phibro belongs, has registered an increase of 9.4%. Over the past three months, the company's shares saw a decrease of 4.1%, while the S&P 500 declined by 4.1%. In comparison, the sector experienced an increase of 8% during this timeframe.